drugset / Trial / NCT07106918

A Clinical Trial of SIBP-A16 Injection in Healthy Adults

NCT07106918

Phase 0 Recruiting 140 enrolled Shanghai Institute Of Biological Products
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is a randomized, double-blind, placebo/positive control Phase Ia clinical trial evaluating the safety, tolerability, and pharmacokinetics of SIBP-A16 injection in healthy adults

Timeline

Start
2025-08-17
Primary completion
2027-04-30
Completion
2027-04-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nirsevimab Monoclonal antibody Intramuscular
Subject SIBP-A16 injection Unknown Intramuscular